Institute for Cancer Research


Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.

The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.

Gunnar Sæter<br>Scientific director
Gunnar Sæter
Scientific director

Scientific production - Institute for Cancer Research

  Publications Doctoral theses
 2016  so far  
2015 220 21
2014 176 25
2013 197 27
2012 175 18
2011 201 22

Annual report 2015 (pdf format)


Latest news

Strønen and Olweus publish article in Science on the use of donor immunity to target cancer

Strønen and Olweus
Strønen and Olweus

Erlend Strønen and Johanna Olweus from the Department of Immunology at the Institute for Cancer Research and the K.G. Jebsen Centre for Cancer Immunotherapy are first and joint last author respectively on a paper recently (May 19th) published in Science (journal impact factor 33.6), entitled "Targeting of cancer neoantigens with donor-derived T cell receptor repertoires".
The international research team - based in Oslo, Amsterdam and Copenhagen - has made a breakthrough methodological development in generating broad and tumour-specific T-cell immune responses based on a novel allogeneic approach. This is a powerful technological advancement which can in the relatively near future be subjected to clinical testing.


Håvard Danielsen and Erik Fosse receive Lighthouse project grants from the Norwegian Research Council

Håvard Danselsen (left), Tine Nordgreen (INTROMAT) and Erik Fosse.
Håvard Danselsen (left), Tine Nordgreen (INTROMAT) and Erik Fosse.

Oslo University Hospital heads projects DoMore! led by Håvard Danielsen from the Institute for Cancer Genetics and Informatics and BIGMED led by Erik Fosse from the Intervention Centre project receive Lighthouse project grant from the Norwegian Research Council's IKTPLUSS area of commitment. The funding for each project is 60 million NOK over a five-year period. 
There were 76 research teams competing for the prestigious grant and only three winners- The third project is INTROMAT, led by Tine Nordgreen from UiB.
The ​DoMore!​ ​team ​is composed ​of experts within several fields, including digital imaging, processing, robotics, pathology, cell biology, surgery and oncology, both in Norway and abroad​​.
The vision behind the BIG data MEDical solution (BIGMED) is to lay the foundation for an ICT platform that addresses the analytic bottlenecks for the implementation of precision medicine, and paves the way for novel big data analytics.


OUS scientists partners in project funded by HORIZON 2020 FAST TRACK TO INNOVATION

"Intelligent needle tracking using ultrasound imaging for improved minimally invasive interventions" supported by EU

Axel R. Sauter (left) and Leiv Arne Rosseland
Axel R. Sauter (left) and Leiv Arne Rosseland

Philips, B.Braun and Oslo University Hospital are partnering in the EU funded INTUI-VIEW project to develop, validate, and bring to the market an intelligent needle tracking technology using ultrasound imaging. The aim of this project is to reliably visualize the needle position in relation to the patient’s anatomy, under ultrasound guidance. The INTUI-VIEW project has been granted €2.36 million.
The participants representing OUH in the project are Axel R. Sauter and Leiv-Arne Rosseland (photo) from the Division of Emergencies and Critical Care at Oslo University Hospital. OUH will receive € 75000 for use in this project, which will be running approximately for 3 years.


Institute for Cancer Research annual report 2015


2015 has been a very good year for ICR, and areas for further improvement include increases in collaboration with clinical researchers, partnerships and coordinator roles in more successful EU grants, and strengthened international visibility. 

Read all the details in the recently published annual report.


OUS scientists co-author Nature article:

Mapping somatic mutations in breast cancer whole genomes

From left: Miriam R. Aure, Ole Chr. Lingjærde, Anita Langerød and Anne-Lise Børresen-Dale
From left: Miriam R. Aure, Ole Chr. Lingjærde, Anita Langerød and Anne-Lise Børresen-Dale

The most comprehensive analysis to date of somatic (acquired) mutations, across whole-genome sequences for breast cancer, is reported in a paper published in the May 2nd edition of Nature (journal impact factor 41.5).
Miriam R. Aure, Anita Langerød, Ole Christian Lingjærde, and Anne-Lise Børresen-Dale from the "Molecular biology of breast cancer group" at the Department of Cancer Genetics has contributed substantially to the study.
A related paper, published in Nature Communications, explores how these mutations relate to aspects of genome structure. Together, the studies highlight the repertoire of genes and mutational processes involved in breast cancer and move us closer to a more complete account of the genetic basis of the disease.


Same, but different? Genetic analysis of five immune mediated diseases reveals molecular taxonomy of chronic inflammation

Tom Hemming Karlsen
Tom Hemming Karlsen

A genetic analysis recently published in Nature Genetics (journal impact factor 29.35) sheds new light on the high comorbidity between primary sclerosing cholangitis (PSC) and inflammatory bowel disease.
Researchers from four large disease consortia, encompassing hundreds of researchers from 26 countries, joined forces to combine data from studies of their respective diseases, amounting to 52,262 patients and 34,213 healthy controls.
“This study is important because it creates a platform for understanding the molecular make-up of each disease, in the future enabling more specified treatment of chronic inflammatory disease”, says Tom Hemming Karlsen, coordinator of one of the participating consortia.